On Monday, Following U.S. Stocks were among the “Top Gainers“: Delek US Holdings, (NYSE:DK), Western Refining, (NYSE:WNR), Cerus (NASDAQ:CERS), Sequenom, (NASDAQ:SQNM)
Delek US Holdings, Inc. (NYSE:DK) proclaimed financial results for its fourth quarter ended December 31, 2014. Delek US stated fourth quarter net revenue of $37.5 million, or $0.64 per diluted share, as compared to a net loss of $(4.7) million, or $(0.08) per basic share, in the quarter ended December 31, 2013. Operating revenue for the fourth quarter 2014 benefited from $60.9 million of net hedging gains, of which $42.6 million were realized.
Delek US Holdings, Inc. (NYSE:DK)’s shares picked up 3.55%, and closed at $37.38, hitting new 52-week high of $37.90. The stock volatility for the week is 3.40%, while for the month remained 4.11%. The company holds consensus target price of $42.00.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed 3.34diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 68.30% and Annual EPS growth for the past 5 years is considered as 142.40%.
The mean recommendation of analysts for this stock is 2.40. (where 1=Buy, 5=Sale).
Delek US Holdings, Inc. (DK) operates as an integrated downstream energy corporation that operates in petroleum refining, WHOLESALE distribution, and convenience store retailing businesses.
Western Refining, Inc. (NYSE:WNR), will declare earnings results for the first quarter ended March 31, 2015, on Tuesday, May 5, 2015, before the open of trading on the New York STOCK EXCHANGE. The Corporation has planned a conference call for May 5, 2015, at 10:00 a.m. EDT to talk about these results.
Western Refining, Inc. (NYSE:WNR), raised 3.46%, and closed at $47.61. The stock has price to sale ratio of 0.30, however, price to book ratio is 4.17. With recent incline, the year-to-date (YTD) performance reflected a 25.12% increase above last year. During the past month the stock gained 16.66%, bringing three-month performance to 28.33% and six-month performance to 8.85%. The mean recommendation of analysts for this stock is 2.50. (where 1=Buy, 5=Sale).
Western Refining, Inc. (WNR), works as an independent crude oil refiner and marketer of refined products. The corporation operates in four segments: Refining, NTI, WNRL, and Retail. The Refining segment owns and operates two refineries that process crude oil and other feed stocks primarily into gasoline, diesel fuel, jet fuel, and asphalt; and markets refined products to various customers, counting WHOLESALE distributors and retail chains.
Cerus Corporation (NASDAQ:CERS), disclosed that the first patient has been enrolled in its TReatment UsE (TRUE) study to make the INTERCEPT Blood System for platelets accessible to regions in the United States with outbreaks of chikungunya and dengue virus under an Expanded Access Investigational Device Exemption (IDE). The American Red Cross is producing INTERCEPT platelet components for the study, which is being conducted in Puerto Rico.
Cerus Corporation (NASDAQ:CERS), enhanced 3.40%, and closed at $4.26. The company holds the market capitalization of 370.53M. For the last twelve months, the stock was able to keep return on equity at -86.70%, while return on assets at -49.60%, in response to its return on investment at -86.40%. Its 20-day moving average decreased -12.05%, below 50-day moving average of -20.62%, above 200-day moving average of -4.77% from the latest market price of $4.26. The mean recommendation of analysts for this stock is 1.50. (Where 1=Buy, 5=Sale).
Cerus Corporation (CERS) along with its partner, Cerus Europe B.V., with as a biomedical products corporation in Europe, the Commonwealth of Independent States, and the Middle East. The corporation develops and commercializes the INTERCEPT Blood System to enhance blood safety.
Sequenom, Inc. (NASDAQ:SQNM), a life sciences corporation committed to enabling healthier lives through the development of innovative products and services, uncovered that its Board of Directors elected Kenneth Buechler, Ph.D. as Chairman of the Board, effective April 1, 2015. Dr. Buechler succeeds Harry Hixson, Jr., Ph.D. who will retire from the position effective March 31, 2015, after 11 years of service.
Sequenom, Inc. (NASDAQ:SQNM), rose 3.39%, and closed at $3.96. The stock has the beta value of 0.41, and its volatility for the week is 4.39%, while for the month it is 3.98%. The company has the market capitalization of $451.83M. The company holds the book value per share of -0.27, whereas cash per share is 4.97. Price to sale ratio is 2.90. Analysts mean recommendation for the stock is said to be 1.70 (where 1=Buy, 5=sale).
Sequenom, Inc. (SQNM) a life sciences corporation, develops and commercializes molecular diagnostics testing services for the women’s health and oncology markets in the United States and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
